Medical Service
Resume:
CURRICULUM VITAE
NAME: MACHTELD ELISABETH HILLEN
PRESENT TITLE: Assistant Professor
Neurology Residency Program Director
Director Adult Neurology Clinic
OFFICE ADDRESS: 90 Bergen Street
DOC 8100
Newark, NJ, 07103
TELEPHONE NUMBER/E-MAIL ADDRESS: ********@*****.***
CITIZENSHIP: USA
EDUCATION:
Undergraduate Education
State University of Groningen
Groningen, the Netherlands
Doctorandus der Geneeskunde August 31, 1992
Graduate and Professional
State University of Groningen
Groningen, the Netherlands
Medical Degree June 29, 1995
POSTGRADUATE TRAINING:
A. Internship and Residencies
Englewood Hospital, Englewood, NJ
Internal Medicine7/96-06/97
State University of New York-Health Science Center at Brooklyn, Brooklyn, New York
Neurology
07/97-06/98
University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ
Neurology
07/98-06/00
B. Fellowship
University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ
Neuroimmunology/Multiple Sclerosis
07/00-06/02
Postdoctoral Appointments
None
MILITARY: none
ACADEMIC APPOINTMENTS:
Department of Neurology and Neurosciences
UMDNJ-NJMS
Assistant Professor07/04-present
HOSPITAL APPOINTMENTS:
Department of Neurology and NeurosciencesThe University Hospital
Attending Neurologist07/04-presentDepartment of MedicineOverlook Hospital
Attending Neurologist08/02-12/06Department of Neurology
East Orange Veterans Administration
Attending Physician without compensation
12/00-06/02Department of MedicineHoly Name Hospital
Attending Neurologist at the Bernard Gimbel Multiple Sclerosis Center
10/00-06/02
OTHER EMPLOYMENT OR MAJOR VISITNG APPOINTMENTS: none
PRIVATE PRACTICESummit Medical Group, Summit, NJ
08/02-06/04
LICENSURE: Medical Doctor 25MA07102500 06/30/2013
DRUG LICENSURE:
CDS: D07832900 10/31/2012
DEA: BH6925486 10/31/2012
CERTIFICATION: American Board of Neurology and Psychiatry Neurology 51287 Certification
contingent on meeting MOC requirements (valid)
MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:
American Academy of Neurology
Consortium of Neurology Program Directors
Member
2008-present
Association of University Professors in Neurology
Member
2004-present
American Academy of Neurology
Active Member
1998-present
American Academy of Neurology
Consortium of Clerkship Directors
Member
2004-2010
HONORS AND AWARDS:
The Raymond A. Troiano Golden Hammmer Award, presented by the Neurology Residents to a
Faculty member in Recognition for Outstanding Teaching
6/21/12
Advancing Hope Award
Awarded by the NJ Chapter of the Huntington s Disease Society of America to the staff of
the Samuel L. Baily University Huntington s Disease Center
5/20/12
Appreciation for Outstanding Leadership as neurology residency program director
Awarded by the Class of 2011
06/16/2011
A. B. Baker Teaching Recognition Award for excellence in neurologic education,
Awarded by the American Academy of Neurology
04/27/2009
Certificate of Excellence in recognition of outstanding teaching
Awarded by the neurology residents
06/24/2009
Nomination Golden Apple Award for teaching New Jersey Medical School
Awarded by NJMS Class of 2009
04/04/2009
Golden Hammer Award in recognition of teaching excellence
Awarded by the neurology residents
06/2007
BOARDS OF DIRECTORS/TRUSTEES POSITIONS: none
SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:
SERVICE ON MAJOR COMMITTEES:
International: none
National: Advisory Committee for Treatment of Late Stage Huntington s Disease, 3/31/12
University of Medicine and Dentistry of New Jersey-New Jersey Medical School:
Institutional Setting Committee, 1/12-present
Search Committee Psychiatry Chair, 11/11-present
Graduate Medical Education Committee, 8/08-present
Clinical Curriculum Committee, 07/04-5/10
The University Hospital:
Epic Steering Committee, 2/11-present
Ambulatory Care Committee, 10/06-present
Charity Care Management Team, 10/10-3/11
Department of Neurology and Neurosciences:
Residency Curriculum Review Committee 07/04-present
Residency Selection Committee 07/04-present
Editorial Boards: none
AdHoc Reviewer: none
SERVICE ON GRADUATE SCHOOL COMMITTEES: none
SERVICE ON HOSPITAL COMMITTEES: See Above
SERVICE TO THE COMMUNITY:
Ask the Doctor, Expert Panelist
The Sharing and Caring Educational Conference of the New Jersey Chapter of the
Huntington s Disease Society of America, 05/12
SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE: none
SPONSORSHIP OF POSTDOCTORAL FELLOWS: none
TEACHING RESPONSIBILITIES:
Lectures or Course Directorships
UMDNJ-New Jersey Medical School,
Neurology Residency Program Director, 08/08-present
UMDNJ-New Jersey Medical School,
Clerkship Co-Director Psychiatry/Neurology Clerkship, 06/06-05/10
UMDNJ-New Jersey Medical School,
Clerkship Director, Neurology Clerkship, 07/04-06/07
UMDNJ-New Jersey Medical School
Adult Neurology Residency, various residency related topics, 2 hours per month,
07/04-present
UMDNJ-New Jersey Medical School
Mind, Brain and Behavior Course, Clinical Correlation Various topics, 4 hours per year,
04/05-present
UMDNJ-New Jersey Medical School
Mind, Brain and Behavior Course, Auditory System, 1 hour per year
04/05-present
UMDNJ-New Jersey Medical School
Mind, Brain and Behavior Course, Cranial Nerve Review, 1 hour per year, 04/07-05/09
UMDNJ-New Jersey Medical School,
Neurology Clerkship Lectures, Various Neurologic Topics, 07/04-05/09
UMDNJ-New Jersey Medical School
Mind, Brain and Behavior Course, Dementia, Integrated Conference
2 hours, 05/06
UMDNJ-New Jersey Medical School
Mind, Brain and Behavior Course, Cranial Nerves, 2 hours, 04/05
Research Training
Post Doctoral Fellows: none
Pre Doctoral Students: none
CLINICAL RESPONSIBILITIES:
Director Adult Neurology Clinic
The University Hospital, Newark, NJ
07/04-present
Attending Physician
General Neurology Service
The University Hospital, Newark, NJ
07/04- present
Attending Physician
Stroke Service
The University Hospital, Newark, NJ
12/04- present
Neurologist
Samuel L. Baily University Huntington s Disease Family Service Center
UMDNJ-NJMS, UMDNJ-RWJMS and Leisure Chateau Care and Rehabilitation Center
07/04-present
GRANT SUPPORT:
Principal Investigator
Biogen Idec, Inc, A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-
Controlled Study to evaluate the Benefits of Switching Therapy (Glatiramer Acetate or
Interferon Beta 1a) to natalizumab in Patients with Relapsing Remitting Multiple
Sclerosis, 10/10-03/11, $8,078
Serono, A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical
trial of oral cladribine in subjects with a first clinical event at high risk of
converting to MS, 03/09-12/10, $2500
Acorda Therapeutics, Inc, Open-Label Extension Study to Evaluate Safety, Tolerability and
Activity of Oral Fampridine-SR in Patients with Multiple Sclerosis, who participated in
the MS-F204 Trial, 10/07-09/10, $32,856
Bayer HealthCare, Real-World Betaseron Outcomes Study (ROBUST), A twelve-month, US
prospective, observational, single-arm, multicenter outcomes study of Inteferon
(Betaseron) given every other day for relapsing multiple sclerosis, 11/07-11/09, $2,500
Acorda Therapeutics, Inc, Double-Blind, Placebo-Controlled, Parallel Group Study to
Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d) in Patients with Multiple
Sclerosis, 04/07-12/08, $39,650
Abbott Laboratories, A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-
Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12
Antibody ABT-847 in Subjects with Multiple Sclerosis with a 24-Week Double-Blind Active
Extension Phase, 1/05-4/05
Co-Investigator
Samuel L. Bailey University Huntington s Disease Family Service Center, 07/04-present,
15% Salary Support
Biogen Idec, Inc, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of
the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary
Progressive Multiple Sclerosis, 9/11-present
Biogen Idec, Inc, JCV Antibody Program in Patients with Relapsing Multiple Sclerosis
Receiving or Considering treatment with Tysabri: STRATIFY-2, 02/11-present
Actelion Pharmaceuticals Ltd, Multicenter, randomized, double-blind, placebo-controlled,
parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of
three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four
weeks in patients with relapsing-remitting multiple sclerosis, 03/10-9/11
Serono, A Phase IIIb, Double Blind, Placebo Controlled Multi-Centre, Parallel Group,
Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects
with Relapsing Multiple Sclerosis Who Have Completed Trial 25643, 05/08-1/12
Serono, A Phase II, Multi-Center, Randomized, Double Blind, Placebo Controlled, Safety,
Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy with Rebif New
Formulation in Multiple Sclerosis Subjects with Active Disease, 03/08-5/12
Biogen Idec, TYGRIS: TYSABRI Global Observational Program in Safety, 2/08-present
Genzyme Corporation, A Phase 3, Randomized, Rater-and Dose-Blinded Study Comparing Two
Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly
Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing-Remitting Multiple
Sclerosis Who Have Relapsed On Therapy, 11/07-12/08
Co-Investigator, Serono, A Phase III, Randomized, Double Blind, 3 Arm, Placebo Controlled
Multi-Centre Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects with
Relapsing Multiple Sclerosis, 05/06-5/08
NIH/NIDS, Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (
WARCEF), 10/05-
6/11
Bayer HealthCare Pharmaceuticals Inc, The BEYOND STUDY: Betaferon/Betaseron Efficacy
Yielding Outcomes of a New Dose, 8/05-1/08
Bayer HealthCare Pharmaceuticals Inc, Phase IV, Rater-Blinded, Randomized Study,
Comparing the Effects of 250 ug of Betaseron with 20 mg of Copaxone in Patients with
Relapsing-Remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI
with Triple-Dose Gadolinium, 7/05-7/09
Abbott Laboratories, A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-
Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12
Antibody ABT-847 in Subjects with Multiple Sclerosis With a 24-Week Double-Blind Active
Extension Phase, 5/05-8/05
Boehringer Ingelheim Pharmaceuticals, Inc, PRoFESS-Prevention Regimen for Effectively
avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox
vs. Clopidrogel & Aspirin, With and Without Micardis, 2/05-10/05
C. Pending: none
PUBLICATIONS:
Refereed Original Article in Journal
Elenein RG, Sharer LR, Cook SD, Pachner AR, Michaels J, Hillen ME. A second case of
Marburg's variant of multiple sclerosis with vasculitis and extensive demyelination. Mult
Scler. 2011;17:1531-1538.
Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson s disease. Neurology
1996 Nov; 47(5): 1180-1183
Hillen ME, Wagner ML, Sage JI. Subclinical orthostatic hypotension is associated with
dizziness in elderly Parkinson s disease patients. Arch Phys Med Rehabil
1996 Jul; 77(7): 710-712
Professional:
Chief Resident Work Shop, UMDNJ-NJMS, Newark, NJ, Management 101, 05/14/12
Grand Rounds, Department of Psychiatry, UMDNJ-RWJ, Piscataway, NJ, Huntington s Disease,
11/3/11
Key Note Speaker, American Medical Women s Association, UMDNJ-NJMS, Newark, NJ, 3/15/10
Grand Rounds, Department of Neurology and Neuroscience, UMDNJ-NJMS, Newark, NJ,
Huntington s Disease, 12/3/08
Grand Rounds, Department of Obstetrics and Gynecology, UMDNJ-NJMS, Newark, NJ, Common
Neurologic Problems in Pregnancy, 10/8/08
CV-Hillen
Page of
Contact this candidate